GT
CPRX

Glenmede Trust’s Catalyst Pharmaceutical CPRX Stock Holding History

Glenmede Trust’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14M Sell
565,424
-52,794
-9% -$1.26M 0.07% 244
2025
Q4 		$14.4M Buy
+618,218
New +$13.8M 0.07% 245
2025
Q1 		$2.08M Sell
85,977
-8,709
-9% -$196K 0.01% 549
2024
Q4 		$1.98M Sell
94,686
-7,346
-7% -$158K 0.01% 554
2024
Q3 		$2.03M Buy
102,032
+433
+0.4% +$8.03K 0.01% 555
2024
Q2 		$1.57M Buy
101,599
+1,249
+1% +$19.4K 0.01% 603
2024
Q1 		$1.6M Sell
100,350
-328
-0.3% -$4.94K 0.01% 617
2023
Q4 		$1.69M Buy
100,678
+52,300
+108% +$715K 0.01% 587
2023
Q3 		$566K Buy
48,378
+20,080
+71% +$269K ﹤0.01% 807
2023
Q2 		$469K Hold
28,298
– – ﹤0.01% 848
2023
Q1 		$469K Buy
+28,298
New +$467K ﹤0.01% 853
2022
Q4 		– Sell
-17,101
Closed -$219K – 1294
2022
Q3 		$219K Sell
17,101
-398
-2% -$4.72K ﹤0.01% 1060
2022
Q2 		$122K Sell
17,499
-4,802
-22% -$35.2K ﹤0.01% 1137
2022
Q1 		$184K Hold
22,301
– – ﹤0.01% 1148
2021
Q4 		$150K Hold
22,301
– – ﹤0.01% 1176
2021
Q3 		$117K Buy
+22,301
New +$122K ﹤0.01% 1167
2020
Q4 		– Sell
-2,414
Closed -$7K – 1438
2020
Q3 		$7K Buy
2,414
+1,579
+189% +$6.17K ﹤0.01% 1987
2020
Q2 		$3K Buy
+835
New +$3.75K ﹤0.01% 2170

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Glenmede Trust's CPRX Position: Q1 2026 in Review

Glenmede Trust reduced its Catalyst Pharmaceutical (CPRX) stake by 8.5% in Q1 2026, selling an estimated $1.26M and leaving 565,424 shares worth $14M. The position accounts for 0.07% of the portfolio, ranked #244.

Glenmede Trust first reported a position in CPRX in Q2 2020 and has held it in 18 quarters since. The position peaked at $14.4M in Q4 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Glenmede Trust held 565,424 shares of Catalyst Pharmaceutical worth $14M as of Q1 2026.
  • Glenmede Trust sold 52,794 Catalyst Pharmaceutical shares in Q1 2026, an estimated $1.26M.
  • Catalyst Pharmaceutical made up 0.07% of Glenmede Trust's portfolio in Q1 2026, its #244 holding.
  • Glenmede Trust first reported a position in Catalyst Pharmaceutical in Q2 2020 and has held it in 18 quarters since.
  • Glenmede Trust's Catalyst Pharmaceutical position peaked at $14.4M in Q4 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Glenmede Trust's 13F filing for Q1 2026, filed 26 May 2026.